Safety and Effectiveness of Japanese Herbal Kampo Medicines for Treating Hyperemesis Gravidarum
Not Applicable
- Conditions
- Hyperemesis gravidarum
- Registration Number
- JPRN-UMIN000032706
- Lead Sponsor
- The University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 100000
Inclusion Criteria
Not provided
Exclusion Criteria
We excluded mothers aged under 19 years.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety outcomes included newborns' congenital anomalies, low birthweight (ICD-10, P070 or P071), and preterm birth (P072 or P073). Congenital anomalies were defined according to the criteria of the Congenital Anomaly Register for Oxfordshire, Berkshire and Buckinghamshire.
- Secondary Outcome Measures
Name Time Method For mothers with hyperemesis gravidarum, we defined effectiveness outcomes as unplanned hospital admission for treating hyperemesis gravidarum and total medical costs during pregnancy within 20 weeks of gestation.